Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options.

A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can invade other organs too in an aggressive way. The third most prevalent type of cancer in the US and the fourth most common form of cancer worldwide, Prostate Cancer is the most leading cause of death in men after lung cancer. 

According to the American Cancer Society (2019), One in Nine men in the United States is diagnosed with prostate cancer at some point in their lives. 

Symptoms such as burning or pain during urination, or troubles and frequent urges to urinate, loss of bladder control are some of the symptoms often neglected. Others include blood in urine and semen, erectile dysfunction, painful ejaculation, swelling in pelvic areas, and leg, and pain and numbness in lower limbs.  However, in most of the Prostate Cancer cases, the signs and symptoms are not that apparent at early stages; hence cancer manages to escape to other organs of the body. 

Timely diagnosis of not just Prostate Cancer but of any type of cancer is one of the most critical steps to increase the survival rate of cancer patients. Moreover, lack of awareness and negligence observed among men for their health often results in overlooking of the early signs of cancer, that can form the basis of the elimination of cancer from its root.

According to DelveInsight’s Prostate Cancer Epidemiological analysis, by 2020, a total of 7,494,882 males will be diagnosed with it in the 7MM, and the US alone will account for 3,478,728 Prostate Cancer prevalent cases. 

Prostate Cancer treatment options comprise of several therapies based on the stage of the tumor.   Several factors, such as age, history, sub-type, the position of tumor, are taken into account while prescribing got treatment for Prostate Cancer. For low-risk Prostate Cancer, Active surveillance is the preferred standard of care, involving routine clinical observation of a patient’s prostate cancer and PSA testing. Then there is Radical Prostatectomy (RP) is also suggested in cases where the Cancer is limited to prostate glands. Apart from this, Radiation therapy is an effective treatment for Prostate Cancer and can be delivered from outside of the body (External Beam Radiation Therapy (EBRT)) or radioactive sources can be placed inside the body within or near Cancer or the organ containing Cancer (brachytherapy); this is often called an implant or seeds. Furthermore, some patients are eligible to receive hormone therapy before, during, and sometimes after radiation treatment that mainly controls the body’s production of the male sex hormone testosterone (androgen). It is accomplished using a combination of luteinizing hormone-releasing hormone (LHRH) agonist and a non-steroidal antiandrogen; for this reason, hormone therapy is often called androgen deprivation therapy. Some of the LHRH agonists available in the Prostate Cancer Market are Leuprolide (Lupron, Eligard), Goserelin (Zoladex), Triptorelin (Trelstar), and Histrelin (Vantas). Chemotherapies such as Docetaxel (Taxotere), Cabazitaxel (Jevtana), Mitoxantrone (Novantrone), and Estramustine (Emcyt) are also used in case of metastasized Prostate Cancer, however, is not the standard of care for the patients. 

Even though recent years have witnessed certain progress in understanding the underlying genetic basis that drives prostate cancer, which has proved to be beneficial in developing novel therapeutic targets, identifying biomarkers for early detection or in distinguishing between aggressive and indolent disease, and to predict treatment outcome, there are still unmet needs prevailing in the Prostate Cancer Market such as effective diagnostics tool for an early screening of Prostate Cancer. 

The establishment of better diagnostic tools—preferably non-invasive or minimally invasive that would permit accurate detection and assessment of prostate cancer, especially in terms of stratifying risk for disease progression in men confirmed by biopsy to have this cancer is the need to the present time to increase the survival rates of the Prostate Cancer Patients.

What are the driving forces behind increasing Prostate Cancer Market Size?

To address the unmet clinical needs, a deep understanding of the Prostate Cancer Market and heightened R&D in the domain is imperative. At present, several companies have indulged themselves, their time and money in initiating clinical trials investigating the novel treatments options, enhancing the existing ones with the aim of strengthening their Prostate Cancer Pipeline and portfolio. Companies like AstraZeneca/Merck Sharp & Dohme (Lynparza), Bristol-Myers Squibb (Opdivo), Novartis (Lutathera), Myovant Sciences (Relugolix), Janssen Research & Development (Niraparib), Hinova Pharmaceuticals USA (HC-1119), Hoffmann-La Roche (Ipatasertib), Pfizer/Astellas Pharma (Talazoparib), Clovis Oncology (Rucaparib), Advantagene or Candel Therapeutics (ProstAtak), and Merck Sharp & Dohme (Keytruda) and several other investigating their key products in the Prostate Cancer Market for the management of the disease.

With over a dozen companies in working in the Prostate Cancer Market, the current developmental Prostate Cancer Pipeline looks very robust. Besides, the rich and novel Prostate Cancer Pipeline, the dynamics of the Prostate Cancer market is anticipated to change in the coming decade owing to the improvement facilitated by the rise in the number of healthcare spending across the world, increasing Prostate Cancer prevalence, increasing geriatric population, betterment in diagnostics tools such as increased biomarker testing and an understanding of the disease among men are other market drivers fueling the Prostate Cancer Market ahead.

What is Prostate Cancer?

Prostate Cancer is a cancer of prostate gland, which is a part of male reproductive system. It is the fourth most common worldwide and third most prevalent type of cancer in the US.

At what CAGR is Prostate Cancer Market size expected to grow for the study period of 2017-30?

Prostate Cancer Market size is expected to increase at a CAGR of 8.1% for the study period 2017-30.

Which country is expected to dominate the Prostate Cancer Market in the 7MM?

Among 7MM countries, the US is anticipated to occupy the most substantial chunk of the Prostate Cancer Market size by 2030.

What is the Prostate Cancer prevalence expected by the end of 2020 in the 7MM?

Prostate Cancer prevalence in the 7MM is expected to reach 7,494,882 by 2020.

Which country is expected to account for the most significant prevalent cases for Prostate Cancer in the 7MM?

The United States is expected to account for the highest Prostate Cancer prevalent cases.

How is the epidemiology of Prostate Cancer segmented?

Prostate Cancer epidemiology is segmented into Age-Specific Cases of Prostate Cancer, Total Treated Cases of mHSPC/CSPC and CRPC, Total Non-Metastatic and Metastatic Cases of CSPC/HSPC and CRPC, Total Diagnosed Cases of Prostate Cancer, Total Diagnosed Cases of Prostate Cancer patients by Clinical Stages and Total Treated cases of Non-Metastatic CSPC/HSPC and CRPC for the study period of 2017-30 for the 7MM.

What are the therapies available in the Prostate Cancer market?

The marketed therapies in the Prostate Cancer market are Xofigo (radium Ra 223 dichloride) of Bayer Health Care, Xtandi (Enzalutamide) of Astellas Pharma, Amgen’s Prolia (denosumab), Janssen’s Erleada (apalutamide), Sanofi’s Jevtana (Cabazitaxel) and Nubeqa (Darolutamide/ODM-201) of Bayer HealthCare/Orion Corporation.

What are the key companies working to advance the Prostate Cancer market?

AstraZeneca, Bristol-Myers Squibb, Novartis, Myovant Sciences, Janssen Research & Development, Hinova Pharmaceuticals USA, Hoffmann-La Roche, Pfizer/Astellas Pharma, Clovis Oncology, Advantagene or Candel Therapeutics, and Merck Sharp & Dohme along with others are the major pharma companies working to fuel the Prostate Cancer market.

What are the emerging therapies in the Prostate Cancer Pipeline for the study period of 2017-30?

Prostate Cancer Pipeline appears robust comprising Lynparza, Rucaparib, Opdivo (nivolumab), 177Lu-PSMA-617, Niraparib ± Abiraterone Acetate, HC-1119 (Deuterated form of enzalutamide), Ipatasertib (RG7440) + Abiraterone Acetate, Talazoparib ± Enzalutamide, ProstAtak (AdV-tk) + valacyclovir, Relugolix, Capivasertib, Seviteronel, PRX302 (topsalysin), and RV001.